Private Trust Company’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Private Trust Company’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-125	Closed	-$7.66K	–	2367
2023 Q2	$7.66K	Hold	125	–	–	﹤0.01%	1731
2023 Q1	$7.85K	Buy	+125	New	+$8.05K	﹤0.01%	1670
2014 Q4	–	Sell	-700	Closed	-$32K	–	919
2014 Q3	$32K	Hold	700	–	–	0.01%	684
2014 Q2	$31K	Hold	700	–	–	0.01%	708
2014 Q1	$29K	Buy	+700	New	+$30K	0.01%	648

Other funds holding PBE

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Private Trust Company's PBE Position: Q3 2023 in Review

Private Trust Company sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2023, closing a stake of 125 shares — an estimated $7.66K sold.

Private Trust Company first reported a position in PBE in Q1 2014 and held it in 5 quarters. The position peaked at $32K in Q3 2014. 97 funds tracked by Wall St. Rank hold PBE as of Q3 2023.

Private Trust Company reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2023 after selling out during the quarter.
Private Trust Company sold 125 Invesco Biotechnology & Genome ETF shares in Q3 2023, an estimated $7.66K.
Private Trust Company first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and held it in 5 quarters.
Private Trust Company's Invesco Biotechnology & Genome ETF position peaked at $32K in Q3 2014.
97 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2023.

Based on Private Trust Company's 13F filing for Q3 2023, filed 18 Oct 2023.